Multidisciplinary team approach for identifying potential candidate for transcatheter aortic valve implantation. by �떖�옱愿� et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 5   September 20141246
Multidisciplinary Team Approach for Identifying Potential 
Candidate for Transcatheter Aortic Valve Implantation  
Sung-Jin Hong,1 Myeong-Ki Hong,1,2 Young-Guk Ko,1 Donghoon Choi,1 Geu-Ru Hong,1 
Jae-Kwang Shim,3 Young-Lan Kwak,3 Sak Lee,4 Byung-Chul Chang,4 and Yangsoo Jang1,2
Divisions of 1Cardiology, 3Anesthesiology and Pain Medicine, and 4Cardiovascular Surgery, Severance Cardiovascular Hospital, 
Yonsei University College of Medicine, Seoul; and 2Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Received: August 12, 2013
Revised: November 14, 2013
Accepted: November 25, 2013
Corresponding author: Dr. Myeong-Ki Hong,  
Division of Cardiology, 
Severance Cardiovascular Hospital, 
Yonsei University College of Medicine, 
50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-8458, Fax: 82-2-2227-7943
E-mail: mkhong61@yuhs.ac 
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2014
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: We sought to evaluate the clinical usefulness of decision making by a 
multidisciplinary heart team for identifying potential candidates for transcatheter 
aortic valve implantation (TAVI) in patients with symptomatic severe aortic steno-
sis. Materials and Methods: The multidisciplinary team consisted of two inter-
ventional cardiologists, two cardiovascular surgeons, one cardiac imaging special-
ist, and two cardiac anesthesiologists. Results: Out of 60 patients who were 
screened as potential TAVI candidates, 31 patients were initially recommended as 
appropriate for TAVI, and 20 of these 31 eventually underwent TAVI. Twenty-two 
patients underwent surgical aortic valve replacement (AVR), and 17 patients re-
ceived only medical treatment. Patients who underwent TAVI and medical therapy 
were older than those who underwent surgical AVR (p<0.001). The logistic Euros-
core was significantly highest in the TAVI group and lowest in the surgical AVR 
group (p=0.012). Most patients in the TAVI group (90%) and the surgical AVR 
group (91%) had severe cardiac symptoms, but only 47% in the medical therapy 
group had severe symptoms. The cumulative percentages of survival without re-
hospitalization or all-cause death at 6 months for the surgical AVR, TAVI, and 
medical therapy groups were 84%, 75%, and 28%, respectively (p=0.007, by log-
rank). Conclusion: TAVI was recommended in half of the potential candidates fol-
lowing a multidisciplinary team approach and was eventually performed in one-
third of these patients. One-third of the patients who were initially considered 
potential candidates received surgical AVR with favorable clinical outcomes.
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INTRODUCTION
Aortic stenosis disease (AS) is a common native valve disease found in up to 5% 
of the elderly population.1 Surgical aortic valve replacement (AVR) is the standard 
treatment for patients with symptomatic severe AS.2 However, despite the accept-
ed results of conventional surgery, surgical risk is markedly increased in elderly 
patients with comorbidities. Additionally, several registries have demonstrated that 
about one-third of patients are considered too high-risk for conventional open heart 
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access site. This study was approved by the Institutional 
Review Board of our institute, and written informed con-
sent was obtained from each patient.
After the systematic work-up, either TAVI or surgical 
AVR was recommended by our multidisciplinary heart 
team. This team consisted of two interventional cardiolo-
gists, two cardiothoracic surgeons, one cardiac imaging 
specialist, and two cardiac anesthesiologists. When conven-
tional open heart surgery was considered to be too risky, 
TAVI was recommended to the patient. The Euroscore, co-
morbidities, frailty, and mobility were taken into account by 
the multidisciplinary heart team approach. During the mul-
tidisciplinary heart team approach, all patients separately 
and independently met and discussed their options with at 
least one interventional cardiologist, one cardiac imaging 
specialist, and two cardiovascular surgeons. Risks and ben-
efits of the different treatment modalities in terms of surviv-
al, relief of symptoms, quality of life, and potential compli-
cations were described independently by each member of 
the multidisciplinary heart team. The decision making by 
the multidisciplinary heart team was determined in a con-
ference meeting with attendance of all seven members and 
involved in-depth discussion and complete agreement of 
the treatment modalities among the seven members. This 
decision by the multidisciplinary heart team was reported to 
the patients, and final decisions were made by the patients.
All TAVI procedures were performed in a hybrid operat-
ing room with a specially equipped angiography system. 
The procedure was previously reported in detail.12-14 Briefly, 
the femoral artery was the preferred access site. Subclavian 
(n=2) or transaortic access (n=1) was considered when 
femoral access was not suitable for advancing the large vas-
cular sheath. All patients had transvenous temporary cardi-
ac pacing during the procedure. Balloon valvuloplasty with 
rapid ventricular pacing (150 to 200 beats/min) was per-
formed prior to prosthetic valve deployment in 11 patients. 
Positioning and deployment of the prosthetic valve was per-
formed under fluoroscopic guidance. All patients were im-
planted with a self-expandable prosthesis, the AccuTrak Cor-
eValve System (Medtronic, Minneapolis, MN, USA) under 
general anesthesia. Valve sizes of 26 mm (n=10), 29 mm 
(n=9), and 31 mm (n=1) were used according to the annu-
lus diameter. Immediately after deployment of the prosthetic 
valve, transesophageal echocardiography was performed to 
confirm good motion of the prosthetic valve and to identify 
any paravalvular leakage. Post-stent balloon dilation was 
performed in five patients to relieve paravalvular leakage.
surgery and remain untreated.3,4 Transcatheter aortic valve 
implantation (TAVI) was developed as an alternative to sur-
gical AVR in this high-risk patient population. TAVI does 
not require cardiopulmonary bypass or sternotomy. Thus, 
identification of high-risk surgical patients is imperative for 
adequate selection of TAVI candidates. Although a number 
of methods for risk stratification of patients for cardiac sur-
gery have been reported, they have limitations because their 
ability to predict actual events is reduced in high-risk and 
elderly patients.5,6 Moreover, no TAVI-specific scoring sys-
tem for those patients has been developed.7,8 Therefore, a 
multidisciplinary heart team approach is currently recom-
mended from the early stages of patient selection.9 The im-
portance of a multidisciplinary team approach with both 
cardiovascular surgeons and cardiologists may be high-
lighted when performing TAVI with required surgical pro-
cedures or as back-up and particularly in a learning period 
of TAVI.8,10,11
The purpose of this study was to examine the impact of 
this multidisciplinary heart team approach on our clinical 
practice in relation to patient selection, treatment, and out-
comes in patients with symptomatic severe AS. 
MATERIALS AND METHODS
　　　
In January 2011, we began screening patients as potential 
TAVI candidates. Between January 2011 and June 2012, 60 
consecutive patients were prospectively screened as poten-
tial TAVI candidates because they were presumed to be at 
high operative risk (logistic Euroscore >20% or Society of 
Thoracic Surgeons score >10% or other conditions related 
to a high operative risk such as significant frailty). They un-
derwent clinical assessment with transthoracic echocar-
diography. Severe AS was defined as an aortic valve area 
<0.8 cm2, a peak aortic jet velocity >4.0 m/s, or mean aortic 
valve pressure gradient ≥40 mm Hg as seen with transtho-
racic echocardiography. Of the 60 screened patients, one 
patient had mild cardiac symptoms according to the New 
York Heart Association (NYHA) functional class I. Thus, 
59 patients with symptomatic severe AS underwent work-
up for technical feasibility for TAVI. All patients underwent 
cardiac computed tomography and transesophageal echo-
cardiography to define aortic annulus dimensions and to 
evaluate associated anatomical structures for performing 
TAVI. Moreover, aorta computed tomography was per-
formed to determine the technical feasibility of the TAVI 
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AVR, and 2 patients (3%) for medical therapy (Fig. 1). The 
reasons for declining TAVI in 11 of 31 TAVI-recommended 
patients were disagreement of risk or complications of TAVI 
due to a less severe symptomatic status in five patients and 
refusing further intervention despite severe symptoms in six 
patients. The reasons for declining surgical AVR in four of 
the 26 surgical AVR-recommended patients were disagree-
ment of risk or complications of surgery due to a less se-
vere symptomatic status in three patients and refusing fur-
ther intervention despite severe symptoms in one patient. 
Therefore, TAVI and surgical AVR were finally performed 
in 20 and 22 patients, respectively. Medical therapy without 
any aortic valve interventions was performed in 11 patients 
who refused TAVI, four patients who refused surgical AVR, 
and two patients who had moderate AS (after detailed as-
sessment and confirmation with transesophageal echocar-
diography). Two patients with moderate AS were excluded 
for outcome analysis.
The baseline clinical characteristics are presented in Ta-
ble 1. Patients receiving TAVI or medical therapy were old-
er than those who underwent surgical AVR (p<0.001). The 
body mass index was significantly lower in patients receiv-
ing TAVI or medical therapy than in those receiving surgi-
cal AVR. The Society of Thoracic Surgeons risk score and 
the logistic Euroscore were significantly highest in the TAVI 
group and lowest in the surgical AVR group (p=0.047 and 
p=0.012, respectively). Most patients in the TAVI group 
Procedural burden (procedure time and length of inten-
sive care unit stay) and safety outcomes (all-cause mortali-
ty, major stroke, major vascular complications, and acute 
kidney injury) during hospitalization were compared be-
tween the TAVI and surgical AVR groups. The definition of 
each outcome was in accordance with the Valve Academic 
Research Consortium guidelines.9 Moreover, clinical effica-
cy at 3 and 6 months was evaluated as the composite events 
of all-cause mortality and re-hospitalization due to severe 
AS or complications of TAVI or surgical AVR. 
Continuous variables were compared using analysis of 
variance or Student’s t-tests, and categorical variables and 
frequencies were compared using the chi-square test or Fish-
er’s exact test. Survival curves were constructed using the 
Kaplan-Meier method and compared with the log-rank test 
according to the TAVI, surgical AVR, and medical therapy 
groups. All analyses were conducted using SPSS Statistics 
(version 18.0.0, IBM Corp., Armonk, NY, USA). A p-value 
<0.05 was considered statistically significant.
 
RESULTS
 
Of the 59 symptomatic (NYHA functional class ≥II) pa-
tients screened as TAVI candidates, the multidisciplinary 
heart team determined that 31 patients (53%) were appro-
priate candidates for TAVI, 26 patients (44%) for surgical 
Fig. 1. Flow diagram of the multidisciplinary heart team approach. *Two patients offered medical therapy by multidisciplinary heart team because of moder-
ate AS were excluded from outcome analysis. AVR, aortic valve replacement; CT, computed tomography; NYHA, New York Heart Association; TTE, trans-
thoracic echocardiogram; TEE, trans-esophageal echocardiogram; TAVI, transcatheter aortic valve implantation.
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a surgical approach for vascular access; two patients re-
quired transaortic access, one patient required subclavian 
access, and one patient required femoral cut-down. Vascu-
lar complications occurred in two patients; femoral artery 
occlusion after use of a closure device requiring vascular 
surgery in one patient and cardiac tamponade due to right 
ventricular rupture by rapid ventricular pacing requiring 
emergency open thoracotomy after a successful TAVI pro-
cedure in the other patient. In the surgical AVR group, the 
and the surgical AVR group had severe cardiac symptoms 
(90% and 91% had NYHA class III or IV status). In con-
trast, only 47% in the medical therapy group had NYHA 
class III or IV status. Comorbidities were similar among the 
three groups except for more common peripheral artery dis-
ease in the TAVI group (p=0.026).
Procedural characteristics of TAVI and surgical AVR are 
shown in Table 2. In the TAVI group, the procedures were 
successfully performed in all patients. Four patients required 
Table 1. Baseline Characteristics
TAVI (n=20) Surgical AVR (n=22) Medical therapy (n=15) p value
Age (yrs)   82±4   77±3 83±4 <0.001
Men (%)   8 (40) 11 (50)   5 (33) 0.585
Weight (kg)     50±10     58±11 50±8 0.016
Height (cm) 154±9 157±9 154±10 0.496
Body mass index (kg/m2)   21.1±3.3   23.6±3.4 21.3±2.8 0.030
STS score     9.2±4.4     5.8±4.3   6.7±4.3 0.047
Logistic Euroscore     25.9±17.1     13.8±13.0 15.3±6.2 0.012
NYHA classification (%) 0.002
    II   2 (10) 2 (9)   8 (53)
    III or IV 18 (90) 20 (91)   7 (47)
Diabetes mellitus (%)   8 (40)   6 (27)   3 (20) 0.417
Hypertension (%) 15 (75) 14 (64)   8 (53) 0.408
Previous PCI or CABG (%)   7 (35)   3 (14) 0 0.022
Peripheral artery disease (%)   5 (25) 0 1 (7) 0.026
Chronic lung disease (%)   5 (25) 2 (9)   2 (13) 0.352
Creatinine level >2 mg/dL (%) 1 (5) 1 (5)   3 (20) 0.201
Ejection fraction (%)     61±15     61±15   59±13 0.952
Aortic valve area (cm2)     0.67±0.19     0.76±0.25   0.67±0.21 0.296
Peak pressure gradients (mm Hg)     85±28     83±29   76±28 0.662
Mean pressure gradients (mm Hg)     56±20     50±19   48±19 0.471
Pulmonary hypertension (%) 14 (70) 13 (59) 12 (80) 0.398
Mitral regurgitation, moderate to severe (%)   2 (10)   4 (18)   5 (33) 0.220
AVR, aortic valve replacement; CABG, coronary artery bypass graft; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, 
Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.
Table 2. Post-Procedural Results and Complications during Hospitalization
TAVI (n=20) Surgical AVR (n=22) p value
Procedure time (mins) 122±59 247±88 <0.001
Intensive care unit stay (days)   3±1   20±56 0.184
Hospital stay (days)   9±4   31±55 0.084
All-cause mortality 0 0
Major stroke 0 0
Vascular complication (%)   2 (10) 0 0.221
Acute kidney injury (%) 0   9 (41) 0.001
Endocarditis (%) 0 1 (5) 1.000
Cardiac tamponade (%) 1 (5) 0 0.476
Mean pressure gradients (mm Hg) 12±6 16±7 0.064
Ejection fraction (%) 63±9   60±16 0.511
Moderate paravalvular leakage (%)   2 (10) 0 0.221
AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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spectively (p=0.007, by log-rank) (Fig. 2B).
DISCUSSION
The main findings of this prospective study for evaluation of 
a multidisciplinary heart team approach are that 1) half of the 
potential candidates for TAVI were recommended for TAVI, 
and about the other half of the potential candidates for TAVI 
were recommended for surgical AVR through this multidisci-
plinary approach; 2) surgical AVR, TAVI, and medical treat-
ment were eventually performed in similar numbers of po-
tential candidates for TAVI, following the patient’s final 
decision and the multidisciplinary heart team’s decisions; 3) 
although the surgical AVR group and the TAVI group 
showed favorable 6-month clinical outcomes, the medical 
treatment group showed worse 6-month clinical outcomes. 
TAVI has emerged as an alternative treatment modality 
for high-risk or inoperable patients.12,15,16 Although a num-
ber of methods for risk stratification for cardiac surgery are 
commonly used to identify high-risk or inoperable patients, 
incidence of acute kidney injury was significantly higher 
than in the TAVI group (41% vs. 0%, p=0.001). Two out of 
nine patients who had acute kidney injury required dialysis. 
Moderate paravalvular leakage was observed in two pa-
tients (10%) in the TAVI group.
Three months after the procedures, one patient (5%) in 
the TAVI group, one patient (5%) in the surgical group, and 
four patients (27%) in the medical therapy group had died. 
The all-cause mortality at 3 months was not significantly 
different among the three groups (p=0.060). However, cardi-
ac symptoms were significantly improved in both the TAVI 
group and the surgical AVR group (Table 3). Permanent 
pacemaker implantation was performed in one patient 3 
months after TAVI. During a median follow-up period of 
205 days, Kaplan-Meier analysis revealed that the cumula-
tive survival rates at 6 months were 88%, 81%, and 51% 
for the surgical AVR, TAVI, and medical therapy groups, 
respectively (p=0.019, by log-rank) (Fig. 2A). Moreover, the 
rates of cumulative survival rate without re-hospitalization 
or all-cause death at 6 months were 84%, 75%, and 28% for 
the surgical AVR, TAVI, and medical therapy groups, re-
Table 3. Clinical Outcomes at 3 Months
TAVI (n=20) Surgical AVR (n=22) Medical therapy (n=15) p value
All-cause death (%) 1 (5) 1 (5)   4 (27) 0.060
Re-hospitalization (%) 1 (5) 1 (5) 1 (7) 0.959
All-cause death or 
  re-hospitalization (%)
  2 (10) 2 (9)   4 (27) 0.259
NYHA classification (%) 0.007
    II 18 (90) 19 (86)   6 (40)
    III or IV 1 (5) 2 (9)   5 (33)
    Death 1 (5) 1 (4)   4 (27)
AVR, aortic valve replacement; NYHA, New York Heart Association; TAVI, transcatheter aortic valve implantation.
Fig. 2. Kaplan-Meier survival curves for cumulative survival (A) and cumulative survival without rehospitalization or all-cause death (B). AVR, aortic valve re-
placement; TAVI, transcatheter aortic valve implantation.
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disciplinary team approach. From this process, 11 patients 
(36%, 11/31) who were recommended for TAVI and four 
patients (15%, 4/26) who were recommended for surgical 
AVR refused further aortic valve interventions. Although 
this number may seem high, considering previous reports 
that surgical AVR was performed in only one-third to half 
of patients with severe AS in a general clinical practice, it is 
not as high as one can assume.4,19 One of the most common 
reasons for refusal was a less severe symptomatic status, 
which is similar to previous reports.19 Of note, however, 
these patients who did not undergo either TAVI or surgical 
AVR had the worst outcomes of the three groups. The im-
portant clinical decision may sometimes be made by the 
physicians alone without sufficient informed discussion, 
but an in-depth discussion between the multidisciplinary 
heart team and the patients before and after the procedures 
is crucial for further improvement of long-term clinical out-
comes in patients with severe symptomatic AS. It was also 
interesting to note that there is such a high prevalence of re-
fusal of intervention in the population even with severe 
symptoms, especially in those patients who were offered 
TAVI, with 19% (6/31) in the TAVI group and 4% (1/26) in 
the surgical AVR group. The introduction of new proce-
dure, TAVI, without sufficient long term outcome might 
have influenced the confidence of patients. Also, the sub-
stantial costs of TAVI could be another explanation for high 
prevalence of refusal of TAVI. 
This study has some limitations. The number of study pa-
tients was relatively small, and the follow-up duration was 
too short to reach concrete conclusions of the clinical sig-
nificance of the multidisciplinary heart team approach. We 
did not perform additional objective tests to verify the se-
verity of symptoms such as 6-minute walk test, which may 
have an additional prognostic value and be helpful for mon-
itoring the patients in the medical therapy group.
In conclusion, a multidisciplinary heart team approach is 
essential for selecting ideal TAVI candidates from patients 
with symptomatic severe AS. This approach may help to 
select patients who have relatively favorable physical char-
acteristics and can undergo surgical AVR, resulting in im-
proved clinical outcomes. 
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these stratification methods are limited in their ability to pre-
dict early operative outcomes in high-risk or elderly pa-
tients.5,6 Therefore, at least one surgeon, an interventionist, 
and a cardiac imaging specialist commonly review the same 
patient and make joint decisions to prevent inappropriate 
recommendation for procedures that will not clinically ben-
efit those patients.9 A recent randomized study also intro-
duced the concept of a multidisciplinary approach to select 
patients to undergo TAVI; two independent cardiovascular 
surgeons needed to agree that a patient was not eligible for 
conventional surgery and therefore could be included in that 
study.17 However, despite underscoring the clinical signifi-
cance of patient selection through a multidisciplinary ap-
proach, little data exist regarding detailed decision-making 
processes by a multidisciplinary heart team for potential can-
didates for TAVI. One study reported favorable clinical out-
comes following TAVI after a multidisciplinary meeting re-
view of 386 TAVI-screened patients; TAVI was performed in 
151 patients (39%), balloon valvuloplasty alone in 49 pa-
tients, surgical AVR in 48 patients (12%), and medical treat-
ment in 104 patients (27%).18 Findings in our study, follow-
ing a multidisciplinary heart team conference, TAVI and 
surgical AVR were initially recommended in 31 (53%) and 
26 (44%) of 59 potential TAVI candidates, respectively. 
Compared to the TAVI and medical treatment groups, pa-
tients undergoing surgical AVR had a more favorable physi-
cal status (i.e., younger age, higher body mass index, and 
lower Society of Thoracic Surgeons score and logistic Euros-
core). Consequently, patients who underwent surgical AVR 
showed comparable results as those who underwent TAVI. 
Therefore, careful patient selection through a multidisci-
plinary heart team approach led to satisfactory outcomes for 
patients with symptomatic severe AS not only in the TAVI 
group but also in the surgical AVR group. Moreover, the 
team approach enabled adequate selection of relatively low-
er-risk patients who are suitable candidates for surgical AVR 
with good results. This approach could lead to reconsidera-
tion of surgery in some selected patients who were initially 
considered high risk for surgery by other hospitals.
In the decision-making process for aortic valve interven-
tion, patients must actively participate in the final treatment 
decision. Patients must be informed of the upfront risk of 
death, stroke, pacemaker placement, and major vascular 
complications. In our study, all patients were separately in-
formed of selection of treatment modalities with at least 
one interventional cardiologist, one cardiac imaging spe-
cialist, and two cardiovascular surgeons during the multi-
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